Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7343140

COc1ccc2ccc(C(=N)N)cc2c1Nc1ncccn1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PLAU P00749 18/20 0.61
PLG P00747 8/20 0.50
KLK1 P06870 8/20 0.50
PLAT P00750 6/20 0.50
F2 P00734 6/20 0.50
PRSS1 P07477 5/20 0.50
PIK3CG P48736 1/20 0.40
CAMKK2 Q96RR4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7342930 1.00 PLAU (0.61) PLAUPLGKLK1PLATF2
SCHEMBL7343484 0.90 PLAU (0.70) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7856857 0.86 PLAU (0.83) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7336904 0.83 PLAU (0.59) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7339090 0.80 PLAU (0.57) PLAUPLGKLK1PLATF2
SCHEMBL7343131 0.78 KMT2A (0.48) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7337301 0.78 PLAU (0.64) PLAUPLGKLK1PLATF2
SCHEMBL7343324 0.78 PLAU (0.50) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7335260 0.77 PLAU (0.53) PLAUPLGKLK1PLATF2
SCHEMBL7338672 0.77 PLAU (1.00) PLAUPLGKLK1PLATF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0819125-A1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-01-21 EP claimed
WO-1996031492-A1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1996-10-10 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885PLG 10/4885KLK1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.